Aladorian

Drug Profile

Aladorian

Alternative Names: ARM036; ARM036Na; S36; S36Na; S44121; S44121-1; S44121-2

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARMGO Pharma
  • Developer ARMGO Pharma; Servier
  • Class 2 ring heterocyclic compounds; Acids; Antiarrhythmics; Heart failure therapies; Small molecules; Thiazepines
  • Mechanism of Action Ryanodine receptor calcium release channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic heart failure; Ventricular tachycardia

Most Recent Events

  • 17 Aug 2017 Clinical development is ongoing in Heart failure, arrhythmia and ventricular tachycardia in Europe (ARMGO Pharma pipeline, August 2017)
  • 10 Dec 2014 Clinical development is ongoing in Heart failure, arrhythmia and ventricular tachycardia in Europe
  • 02 Feb 2012 Phase-II clinical trials in Ventricular tachycardia in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top